1418318-99-6Relevant articles and documents
Industrial scale-up of enantioselective hydrogenation for the asymmetric synthesis of rivastigmine
Yan, Pu-Cha,Zhu, Guo-Liang,Xie, Jian-Hua,Zhang, Xiang-Dong,Zhou, Qi-Lin,Li, Yuan-Qiang,Shen, Wen-He,Che, Da-Qing
, p. 307 - 312 (2013)
Two efficient processes for the synthesis of rivastigmine, one of the most potent drugs for the treatment of mild-to-moderate dementia of the type presenting in Alzheimer's disease, has been developed. Of particular note is the processes used for the asymmetric hydrogenation by applying the highly efficient chiral spiro catalyst, Ir-SpiroPAP. The first route was easy to scale up in industry and provided the commercial intermediate (S)-3-(1- dimethylaminoethyl)phenol, 6, which is suitable for the manufacture of rivastigmine in active pharmaceutical ingredient (API) demand. The second route was convenient for operation and purification and completed the synthesis of rivastigmine (1) in four steps and 84% overall yield.